MRK: Pipeline advances and strategic deals drive growth, with new assets and AI boosting future potential
Transformation is progressing with strong product launches, positive clinical data, and business development driving growth. Pipeline assets like INT and sac-TMT offer significant upside, while LIPFENDRA is positioned for broad access. AI and global innovation are enhancing R&D efficiency.Based on…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.